

Mohammed Saji Salahudeen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1979439/publications.pdf>

Version: 2024-02-01

38
papers

1,194
citations

623188

14
h-index

395343

33
g-index

41
all docs

41
docs citations

41
times ranked

1532
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. <i>BMC Geriatrics</i> , 2015, 15, 31. | 1.1 | 358 |
| 2 | Comparison of Anticholinergic Risk Scales and Associations with Adverse Health Outcomes in Older People. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 85-90. | 1.3 | 134 |
| 3 | An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. <i>Saudi Pharmaceutical Journal</i> , 2017, 25, 165-175. | 1.2 | 108 |
| 4 | Anticholinergics: theoretical and clinical overview. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 753-768. | 1.0 | 103 |
| 5 | Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013. <i>Gerontology</i> , 2015, 61, 195-202. | 1.4 | 80 |
| 6 | Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2016, 11, e0151084. | 1.1 | 38 |
| 7 | Impact of Anticholinergic Discontinuation on Cognitive Outcomes in Older People: A Systematic Review. <i>Drugs and Aging</i> , 2014, 31, 185-192. | 1.3 | 36 |
| 8 | Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862093789. | 1.0 | 33 |
| 9 | Association between anticholinergic drug burden and mortality in older people: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 319-335. | 0.8 | 31 |
| 10 | Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 108. | 0.6 | 25 |
| 11 | Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. <i>Drugs and Aging</i> , 2016, 33, 305-313. | 1.3 | 23 |
| 12 | Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 586370. | 1.6 | 20 |
| 13 | The Influence of Patient Characteristics on Anticholinergic Events in Older People. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 530-541. | 0.6 | 19 |
| 14 | Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023098. | 1.6 | 18 |
| 15 | A Systematic Review Evaluating the Use of the interRAI Home Care Instrument in Research for Older People. <i>Clinical Gerontologist</i> , 2019, 42, 463-484. | 1.2 | 17 |
| 16 | Pharmacist-led interventions to reduce adverse drug events in older people living in residential aged care facilities: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3672-3689. | 1.1 | 17 |
| 17 | Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3568. | 1.0 | 14 |
| 18 | Deprescribing medications in older people: a narrative review. <i>Drugs of Today</i> , 2018, 54, 489. | 0.7 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Pharmacists as a Source of Advice on Medication Use for Athletes. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 10. | 0.6 | 13 |
| 20 | Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13457. | 1.7 | 11 |
| 21 | Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13489. | 1.7 | 11 |
| 22 | Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 279-284. | 0.7 | 10 |
| 23 | A study of the factors affecting time to onset of lactogenesis-II after parturition. <i>Journal of Pharmacy Research</i> , 2013, 6, 68-72. | 0.4 | 9 |
| 24 | Effectiveness of Interventions to Improve the Anticholinergic Prescribing Practice in Older Adults: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 714. | 1.0 | 8 |
| 25 | Drug-associated non-pyrogenic hyperthermia: a narrative review. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 9-16. | 0.8 | 6 |
| 26 | A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease. <i>Drugs of Today</i> , 2019, 55, 385. | 0.7 | 6 |
| 27 | Outcomes of Medication Misadventure Among People With Cognitive Impairment or Dementia: A Systematic Review and Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2021, 55, 530-542. | 0.9 | 5 |
| 28 | Credentials for a PharmD graduate: The voyage never ends. <i>SAGE Open Medicine</i> , 2015, 3, 205031211558422. | 0.7 | 4 |
| 29 | Ten-year trends in adverse drug reaction-related hospitalizations among people with dementia. <i>Therapeutic Advances in Drug Safety</i> , 2022, 13, 204209862210807. | 1.0 | 4 |
| 30 | Cognitive adverse effects and brain deterioration associated with use of anticholinergic activity medicines in older adults. <i>Evidence-Based Medicine</i> , 2016, 21, 235-235. | 0.6 | 2 |
| 31 | Temporal trends in the use of antidiabetic medicines: a nationwide 9-year study in older people living in New Zealand. <i>Therapeutic Advances in Drug Safety</i> , 2016, 7, 184-194. | 1.0 | 2 |
| 32 | Drug-associated hyperthermia: A longitudinal analysis of hospital presentations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 477-487. | 0.7 | 2 |
| 33 | Eight-Year Trends in Direct-Acting Oral Anticoagulant Dosing, Based on Age and Kidney Function, in Patients With Atrial Fibrillation. <i>Journal of Patient Safety</i> , 2022, 18, 337-341. | 0.7 | 2 |
| 34 | Ten-year trends in prescribing of antiarrhythmic drugs in Australian primary care patients with atrial fibrillation. <i>Internal Medicine Journal</i> , 2021, 51, 1732-1735. | 0.5 | 2 |
| 35 | An overview of pharmacoepidemiology in New Zealand: medical databases, registries and research achievements. <i>New Zealand Medical Journal</i> , 2017, 130, 52-61. | 0.5 | 2 |
| 36 | Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 359-364. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Risk of osteoporosis in patients with atrial fibrillation with and without oral anticoagulant therapy. Expert Review of Clinical Pharmacology, 2022, 15, 1003-1010. | 1.3 | 2 |
| 38 | Actual drug-related harms in residential aged care facilities: a narrative review. Expert Opinion on Drug Safety, 2022, 21, 1047-1060. | 1.0 | 1 |